CL

Cellebrite DI Ltd.

CLBTTechnologyNASDAQ

Software - Infrastructure

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$475.7M
+18.6% YoY
Net Income
$78.3M
+127.7% YoY
EBITDA
$103.1M
+138.8% YoY
Free Cash Flow
$124.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 3 MACD Positive CrossoverHistogram +0.0676, positive momentum
Sep 2 MACD Positive CrossoverHistogram +0.0615, positive momentum
About Cellebrite DI Ltd.

Part of the technology sector, Cellebrite DI Ltd. (CLBT) is listed under Software - Infrastructure. At a $2.88B market cap, Cellebrite DI Ltd. ranks as a mid-cap company within technology. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency.

Where CLBT stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, CLBT finished 15.49% below its 150-day moving average ($13.75) and 21.27% below its 200-day moving average ($14.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CLBT overbought or oversold?

At the September 3, 2026 close, CLBT's RSI(14) was 59.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.88B
P/E (TTM)49.78
Fwd P/E17.53
EPS$0.23
Beta1.15
52W Change-33.7%
ROE12.4%
Analysis

Cellebrite DI Ltd. holds $442.5M in cash against $23.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $124.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 12.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $270.7M (2022) to $475.7M (2025), reflecting a 76% increase over the period.

With cash comfortably exceeding debt, CLBT has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLBT.

Links
More Technology stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms